Valneva joins the phase 3 Covid-19 vaccine club

As the world awaits pivotal US data on Novavax’s Covid-19 jab, plenty of other players are still trying to get in on the second wave of vaccines.

One of the latest, Valneva, pushed VLA2001 into a pivotal UK study yesterday, while Ocugen hopes that its contender, Covaxin, could get the nod in the US on the back of data from a phase 3 trial in India. The latter’s share price climbed 18% yesterday.